Abstract
Abstract.Background: Vitamin D deficiency (VDD) is a major public health problem. There are few comprehensive systematic reviews about the relationship between Vitamin D status and liver and renal disease in Iran.
Methods: We systemically searched the following databases: Web of Science; PubMed; Cochrane Library; Scopus; Science Direct; Google Scholar and two Iranian databases (Scientific Information Database (SID) and IranMedex) up until November 2017 to identify all randomized control trials (RCTs), case control, cross-sectional and cohort studies investigating the association between vitamin D and any form of liver or kidney disease.
Results: Vitamin D insufficiency, or deficiency (VDD), is highly prevalent in Iran, reports varying between 44.4% in Isfahan to 98% in Gorgan. There is also a high prevalence of VDD among patients with liver or kidney disease, and the administration of vitamin D supplements may have beneficial effects on lipid profile, blood glucose, liver function and fatty liver disease, and bone health. Low serum vitamin D levels are related with abnormalities in these laboratory and clinical parameters.
Conclusion: VDD is prevalent in patients with chronic liver or renal disease in Iran. There appear to be several beneficial effects of vitamin D supplementation in vitamin D deficient patients with liver or kidney disease.
References
1 (2008) Analyzing vitamin D in foods and supplements: methodologic challenges. Am J Clin Nutr. 88(2), 554S–557S.
2 (2014) Vitamin D metabolism, mechanism of action, and clinical applications. Chem & Biol. 20(3), 319–329.
3 (2016) Association of low vitamin D levels with metabolic syndrome in hemodialysis patients. Hemodial Int. 20(2), 261–269.
4 (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 87(4), 1080S–1086S.
5 (2011) Vitamin D deficiency and Its cut-off point among young teenagers. Birjand J Med Sci. 18(3), 210–216.
6 (2011) Vitamin D deficiency in 2010: health benefits of vitamin D and sunlight: a D-bate. Nat Rev Endocrinol. 7(2), 73–75.
7 (2014) Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol. 144, 138–145.
8 (2014) New insight of vitamin D in chronic liver diseases. Hepatobiliary Pancreat Dis Int. 13(6), 580–585.
9 (2006) Wood, Vitamin D status and the metabolic syndrome. Nutr Rev. 64(11), 479–486.
10 (2014) Effect of vitamin D supplementation on C-reactive protein in patients with nonalcoholic fatty liver. Int J Prev Med. 5(8), 969–975.
11 (2013) Association between dietary sodium and potassium intake with chronic kidney disease in US adults: a cross-sectional study. Am J Nephr. 37(6), 526–533.
12 (2011) Fluid and nutrient intake and risk of chronic kidney disease. Nephrology. 16(3), 326–334.
13 (1986) The effect of l-αhydroxyvitamin D3 oil cell-mediated immunity in hemodialyzed patients. J Clin Endocrinol & Metabol. 63(5), 1218–1221.
14 (2008) Impact of treatment with oral calcitriol on glucose intolerance and dyslipidemia (s) in hemodialysis patients. Saudi J Kidney Dis Transpl. 19(6), 942–947.
15 (2017) Relationship between vitamin D deficiency and metabolic syndrome in renal transplant patients in Mashhad, Iran. Shiraz E-Med J. 18(3), e40985.
16 (2017) The joanna briggs institute critical appraisal tools for use in JBI systematic reviews checklist for analytical cross sectional studies. The Joanna Briggs Institute: North Adelaide, Australia.
17 (2017) The joanna briggs institute critical appraisal tools for use in JBI systematic reviews checklist for analytical clinical trial studies. North Adelaide, Australia: The Joanna Briggs Institute.
18 (2015) The factors affecting bone density in cirrhosis. Hepat Mon. 15(4), e26871.
19 (2010) Disturbances of parathyroid hormone–vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepat Int. 4(3), 634–640.
20 (2012) Prevalence of vitamin D deficiency and rickets in children with cholestasis in Iran. Acta Medica Iranica. 50(7), 482–485.
21 (2016) Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial. Clin Nutr. 36(6), 1490–1497.
22 (2016) Regression of non-Alcoholic fatty liver by vitamin D supplement: A double-blind randomized controlled clinical trial. Arch Iran Med. 19(9), 631–638.
23 (2016) The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease. Iran J Nurs Midwifery Res. 21(1), 100–104.
24 (2016) Women may respond different from men to vitamin D supplementation regarding cardiometabolic biomarkers. Exp Biol Med. 241(8), 830–838.
25 (2013) Effects of low caloric diet with and without vitamin D supplementation on anthropometric parameters in patients with non-alcoholic fatty liver. Tol beh. 14(6), 410–422.
26 (2017) Serum vitamin D levels and severity of liver dysfunction in cirrhotic patients. Clin Med. 16(8), 402–411.
27 (2015) The effect of vitamin D supplementation on insulin resistance in patients with nonalcoholic fatty liver. J Isfahan Med. 33(342), 1076–1085.
28 (2014) Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 47(1), 70–80.
29 (2017) Prevalence of fatty liver and its risk factors in patients with chronic hepatitis C virus infection in joint congress of the 6th biennial congress of the asian-pacific hepato-pancreato-biliary association and the 29th meeting of japanese society of hepato-biliary-pancreatic surgery. Japan: Blackwell Publishing Asia.
30 (2013) Correlation between serum parathyroid hormone and markers of bone metabolism in hemodialysis patients. J Isfahan Med. 31(244), 1059–1066.
31 (2012) Serum level of vitamin D in patients with kidney transplantation in Gorgan (South East of Caspian Sea), Iran. World App Sci J. 17(2), 172–175.
32 (2011) Bone mineral disorders in pediatric and adolescent renal transplant recipients. Ped Transplan. 15(4), 367–375.
33 (2011) 25-hydroxyvitamin D deficiency in kidney transplant recipients. Iran J Kidney Dis. 5(1), 57–63.
34 (2016) Association between 25-hydroxyvitamin D level and inflammatory and nutritional factors in hemodialysis and peritoneal dialysis patients in Qom, Iran. Iran J Kidney Dis. 10(4), 205–212.
35 (2017) Effects of inactive vitamin D on persistent secondary hyperparathyroidism in patients on hemodialysis. Nephrourol Mon. 9(2), e13156.
36 (2017) Association of vitamin D deficiency with sleep quality in patients under peritoneal dialysis. J Isfahan Med. 35(446), 1192–1196.
37 (2016) The effect of vitamin D administration on serum leptin and adiponectin levels in end-stage renal disease patients on hemodialysis with vitamin D deficiency: A placebo-controlled double-blind clinical trial. J Res Med Sci. 21.
38 (2015) The effect of Vitamin D administration on treatment of anemia in end-stage renal disease patients with vitamin D deficiency on hemodialysis: A placebo-controlled, double-blind clinical trial. J Res Med Sci. 20(8), 745–750.
39 (2012) Vitamin D, parathyroid hormone, and bone mineral density status in kidney transplant recipients. Iran J Kidney Dis. 6(4), 295–299.
40 (2013) Calcium and vitamin D supplementation and risk of kidney stone formation in postmenopausal women. Iran J Kidney Dis. 7(3), 210–214.
41 (2015) Vitamin D Levels after kidney transplantation and the risk of cytomegalovirus infection. Nephrourol Mon. 7(6), e29671.
42 (2007) The influence of serum 25-hydroxy vitamin D levels on helicobacter pylori infections in patients with end-stage renal failure on regular hemodialysis. Saudi J Kidney Dis Transpl. 18(2), 215–219.
43 (2016) Micronutrient intakes and incidence of chronic kidney disease in adults: Tehran Lipid and Glucose Study. Nutrients. 8(4), 217–223.
44 (2016) Assessment of circannual rhythm in plasma level of vitamin D among kidney transplant recipients in Mashhad. Iran J Kidney Dis. 10(4), 224–229.
45 (2012) A 12-week double-blind randomized clinical trial of vitamin D 3 supplementation on body fat mass in healthy overweight and obese women. Nutr J. 11(1), 78–83.
46 (2007) Associations between serum 25-hydroxyvitamin D 3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 17(7), 517–524.
47 (2011) Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci. 56(7), 2124–2129.
48 (2013) High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocrin J. 60(6), 743–752.
49 (2010) High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile. Eur J Clin Nutr. 64(12), 1457–1464.
50 (2012) Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis. 11(1), 42–46.
51 (2012) Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol. 7(2), 358–365.
52 (2016) Serum 25-hydroxyvitamin D as a predictor of hospitalization-free survival in predialysis and dialysis patients with chronic kidney disease: a single-center prospective observational analysis. Kidey Res Clin Pract. 35(1), 22–28.
53 (2014) Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 21(3), 319–329.
54 (2010) Molecular mechanisms for regulation of intestinal calcium absorption by vitamin D and other factors. Crit Rev Clin Lab Sci. 47(4), 181–195.
55 (2006) Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25‐hydroxyvitamin D in chronic kidney disease. Nephrology. 11(6), 555–559.
56 (2006) 25 (OH) Vitamin D 3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol. 38(2), 323–329.
57 (1992) Effects of 1, 25 (OH) 2D3 treatment on lipid levels in uremic hemodialysis patients. Int J Artif Organs. 15(12), 704–707.
58 (1994) Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci. 87(5), 533–538.
59 (2016) Intake of nutrients, fiber, and sugar in patients with nonalcoholic fatty liver disease in comparison to healthy individuals. Int J Prev Med. 9(7), 98–102.
60 (2015) Negative association of plasma levels of vitamin D and miR-378 with viral load in patients with chronic hepatitis B infection. Hepat Mon. 15(6), e28315.
61 (2013) Dietary quality indices and biochemical parameters among patients with non alcoholic fatty liver disease (NAFLD). Hepat Mon. 13(7), e10943.
62 (2012) Frequency of musculoskeletal complications among the patients receiving solid organ transplantation in a tertiary health-care center. Rheumat Int. 32(8), 2363–2366.
63 (2000) Effect of vitamins on the lipid profile of patients on regular hemodialysis. Scand J Urol Nephrol. 34(1), 62–66.
64 (2017) Renal osteodystrophy in End Stage Renal Disease patients in a center in South East of Iran: A cross- sectional study. Int J Clin Skill. 11(1), 41–46.
65 (2014) The evaluation of relationship between vitamin D and muscle power by micro manual muscle tester in end-stage renal disease patients. Saudi J Kidney Dis Transpl. 25(5), 998–1003.
66 (2014) Serum levels of fetuin-A and its relationship with intact parathroid hormone and 25(OH) vitamin D in hemodialysis patients. Urmia J Med Sci. 25(5), 404–407.
